(Q38014923)

27 August 2017

Antibody-drug conjugates - a perfect synergy (English)

1 reference

27 August 2017

1 reference

John R Adair

1

1 reference

27 August 2017

Philip W Howard

2

1 reference

27 August 2017

John A Hartley

3

1 reference

27 August 2017

David G Williams

4

1 reference

27 August 2017

Kerry A Chester

5

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

1191-1206

1 reference

27 August 2017

9

1 reference

Have we overestimated the benefit of human(ized) antibodies?

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Mining human antibody repertoires

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Neonatal Fc receptor: from immunity to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Targeted therapy of cancer: new prospects for antibodies and immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Targeted cancer therapy: conferring specificity to cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Semisynthetic maytansine analogues for the targeted treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

The development of pyrrolobenzodiazepines as antitumour agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Bispecific digoxigenin-binding antibodies for targeted payload delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Enzymatic procedure for site-specific pegylation of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody-targeted immunotherapy for treatment of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Mono-N-terminal poly(ethylene glycol)-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

An engineered selenocysteine defines a unique class of antibody derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Site-specific attachment to recombinant antibodies via introduced surface cysteine residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Design and application of antibody cysteine variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

The role of the VL- and VH-segments in the preferential reassociation of immunoglobulin subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Structural and functional characterization of disulfide isoforms of the human IgG2 subclass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Selective formation of covalent protein heterodimers with an unnatural amino acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Investigational antibody drug conjugates for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Investigational antibody-drug conjugates for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody conjugate therapeutics: challenges and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody-drug conjugate targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Brentuximab Vedotin (SGN-35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Inotuzumab ozogamicin as novel therapy in lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

Suppression of tumour growth in mice by a drug–antibody conjugate using a novel approach to linkage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693473

10.1517/14712598.2012.693473

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference